Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunome, Inc. - Common Stock (NQ:IMNM)

21.50 -0.64 (-2.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunome, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Immunome Appoints Kinney Horn as Chief Business Officer
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Sandra M. Swain to Board of Directors
From Immunome
Via Business Wire
News headline image
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
From Immunome, Inc.
Via Business Wire
News headline image
IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 ↗
IMNM stock results show that Immunome beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
From Immunome, Inc.
Via Business Wire
News headline image
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday? ↗
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. 
Via Benzinga
News headline image
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
From Immunome, Inc.
Via Business Wire
News headline image
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Immunome to Participate in the Leerink Partners Global Biopharma Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue? ↗
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the highs of 2021. David Prince, professional trader at T3 Trading Group, joined... 
Via Benzinga
News headline image
How I Swing Trade Via Strength With Recent Examples ↗
In this video, I explain how I avoid major losses, keep my losses small, and maximize gains. I also provide some recent trades as examples. 
Via Talk Markets
News headline image
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Immunome, Inc.
Via Business Wire
News headline image
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Pricing of Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Announces Proposed Public Offering of Common Stock
From Immunome, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
From Immunome, Inc.
Via Business Wire
News headline image
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile 
From Ayala Pharmaceuticals
Via GlobeNewswire
News headline image
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome - Oncology Is Hot ↗
Immunome, an oncology biomedical company, has gained 27.48% since a buy signal on December 22. 
Via Talk Markets
News headline image
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Phil Roberts as Chief Technical Officer
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Immunome, Inc.
Via Business Wire
News headline image
Immunome Appoints Carol A. Schafer to Board of Directors
From Immunome, Inc.
Via Business Wire
News headline image
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
From Immunome, Inc.
Via Business Wire
News headline image
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
News headline image
Immunome to Present at the Stifel 2023 Healthcare Conference
From Immunome, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.